Cadila Healthcare has gained to a new high on the commencement of the next phase of H1N1 drug by Zydus Cadila.
The stock opened at Rs 805 and gained 2% to a new high of Rs 813. It is now trading with a 1.4% gain at Rs 810. Around 1,214 stocks have been traded on the BSE so far.
The demand for the H1N1 vaccine is expected to be around 60-80 million doses in India, and that the company would focus on marketing the product in India initially.